EP1059939A1 - Verfahren und vorrichtung zur erhöhung der flüssigkeitsdurchflussgeschwindigkeit in einem biologischen gewebe mit mikroporen - Google Patents

Verfahren und vorrichtung zur erhöhung der flüssigkeitsdurchflussgeschwindigkeit in einem biologischen gewebe mit mikroporen

Info

Publication number: EP1059939A1
Authority: EP; European Patent Office
Prior art keywords: flux enhancer; tissue; micropore; flux; reservoir
Prior art date: 1998-03-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP99911120A

Other languages

English (en)

French (fr)

Other versions

EP1059939B1 (de

Inventor

Jonathan A. Eppstein

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Altea Therapeutics Corp

Original Assignee

Spectrx Inc

Altea Technologies Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-06

Filing date

1999-03-05

Publication date

2000-12-20

1999-03-05 Application filed by Spectrx Inc, Altea Technologies Inc filed Critical Spectrx Inc

1999-03-05 Priority to DK99911120T priority Critical patent/DK1059939T3/da

2000-12-20 Publication of EP1059939A1 publication Critical patent/EP1059939A1/de

2004-08-11 Application granted granted Critical

2004-08-11 Publication of EP1059939B1 publication Critical patent/EP1059939B1/de

2019-03-05 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

230000004907 flux Effects 0.000 title claims abstract description 139
238000000034 method Methods 0.000 title claims abstract description 77
239000012530 fluid Substances 0.000 title claims abstract description 22
230000002708 enhancing effect Effects 0.000 title claims abstract description 11
239000003623 enhancer Substances 0.000 claims abstract description 124
239000012528 membrane Substances 0.000 claims abstract description 92
229940079593 drug Drugs 0.000 claims abstract description 50
239000003814 drug Substances 0.000 claims abstract description 50
238000003306 harvesting Methods 0.000 claims abstract description 7
210000001519 tissue Anatomy 0.000 claims description 132
239000000523 sample Substances 0.000 claims description 71
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 15
239000012491 analyte Substances 0.000 claims description 14
239000000126 substance Substances 0.000 claims description 14
239000000758 substrate Substances 0.000 claims description 10
210000003722 extracellular fluid Anatomy 0.000 claims description 8
229910021529 ammonia Inorganic materials 0.000 claims description 7
239000007788 liquid Substances 0.000 claims description 7
239000007787 solid Substances 0.000 claims description 6
-1 anti-prurities Substances 0.000 claims description 3
230000015572 biosynthetic process Effects 0.000 claims description 3
108090000790 Enzymes Proteins 0.000 claims description 2
102000004190 Enzymes Human genes 0.000 claims description 2
102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 2
108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 2
230000004856 capillary permeability Effects 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims description 2
239000002934 diuretic Substances 0.000 claims description 2
229940030606 diuretics Drugs 0.000 claims description 2
210000002744 extracellular matrix Anatomy 0.000 claims description 2
235000013305 food Nutrition 0.000 claims description 2
239000003102 growth factor Substances 0.000 claims description 2
210000003630 histaminocyte Anatomy 0.000 claims description 2
230000002757 inflammatory effect Effects 0.000 claims description 2
239000003112 inhibitor Substances 0.000 claims description 2
239000003921 oil Substances 0.000 claims description 2
210000004379 membrane Anatomy 0.000 description 69
210000003491 skin Anatomy 0.000 description 20
230000003287 optical effect Effects 0.000 description 16
239000000203 mixture Substances 0.000 description 15
239000000463 material Substances 0.000 description 14
150000001875 compounds Chemical class 0.000 description 11
239000000835 fiber Substances 0.000 description 11
238000012544 monitoring process Methods 0.000 description 9
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
238000002679 ablation Methods 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
239000008103 glucose Substances 0.000 description 8
230000008016 vaporization Effects 0.000 description 8
239000008280 blood Substances 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
230000007246 mechanism Effects 0.000 description 7
230000035515 penetration Effects 0.000 description 7
239000011148 porous material Substances 0.000 description 7
238000009834 vaporization Methods 0.000 description 7
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
238000012377 drug delivery Methods 0.000 description 6
238000005070 sampling Methods 0.000 description 6
239000000853 adhesive Substances 0.000 description 5
230000001070 adhesive effect Effects 0.000 description 5
210000004207 dermis Anatomy 0.000 description 5
238000013461 design Methods 0.000 description 5
210000002615 epidermis Anatomy 0.000 description 5
238000010438 heat treatment Methods 0.000 description 5
230000008569 process Effects 0.000 description 5
210000000434 stratum corneum Anatomy 0.000 description 5
238000012546 transfer Methods 0.000 description 5
238000004458 analytical method Methods 0.000 description 4
WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 4
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 3
101800004538 Bradykinin Proteins 0.000 description 3
102400000967 Bradykinin Human genes 0.000 description 3
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 3
108010003541 Platelet Activating Factor Proteins 0.000 description 3
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
239000011358 absorbing material Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000012867 bioactive agent Substances 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
210000004204 blood vessel Anatomy 0.000 description 3
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000002716 delivery method Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000004520 electroporation Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
229960001340 histamine Drugs 0.000 description 3
239000000243 solution Substances 0.000 description 3
229910052721 tungsten Inorganic materials 0.000 description 3
239000010937 tungsten Substances 0.000 description 3
238000007514 turning Methods 0.000 description 3
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
241000282414 Homo sapiens Species 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
239000012620 biological material Substances 0.000 description 2
YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
238000010586 diagram Methods 0.000 description 2
230000005684 electric field Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
RBTKNAXYKSUFRK-UHFFFAOYSA-N heliogen blue Chemical compound [Cu].[N-]1C2=C(C=CC=C3)C3=C1N=C([N-]1)C3=CC=CC=C3C1=NC([N-]1)=C(C=CC=C3)C3=C1N=C([N-]1)C3=CC=CC=C3C1=N2 RBTKNAXYKSUFRK-UHFFFAOYSA-N 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
150000002617 leukotrienes Chemical class 0.000 description 2
230000008018 melting Effects 0.000 description 2
238000002844 melting Methods 0.000 description 2
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
230000000149 penetrating effect Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
230000035807 sensation Effects 0.000 description 2
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
230000037317 transdermal delivery Effects 0.000 description 2
DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
ZAMLGGRVTAXBHI-UHFFFAOYSA-N 3-(4-bromophenyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(CC(O)=O)C1=CC=C(Br)C=C1 ZAMLGGRVTAXBHI-UHFFFAOYSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
206010006784 Burning sensation Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000723346 Cinnamomum camphora Species 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108700021041 Disintegrin Proteins 0.000 description 1
108010003272 Hyaluronate lyase Proteins 0.000 description 1
102000001974 Hyaluronidases Human genes 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
108010003195 Kallidin Proteins 0.000 description 1
FYSKZKQBTVLYEQ-FSLKYBNLSA-N Kallidin Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 FYSKZKQBTVLYEQ-FSLKYBNLSA-N 0.000 description 1
108010093008 Kinins Proteins 0.000 description 1
102000002397 Kinins Human genes 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 description 1
101800000399 Neurokinin A Proteins 0.000 description 1
102400000097 Neurokinin A Human genes 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
239000000006 Nitroglycerin Substances 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229940081735 acetylcellulose Drugs 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000007792 addition Methods 0.000 description 1
229940023184 after bite Drugs 0.000 description 1
ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 1
JTXJZBMXQMTSQN-UHFFFAOYSA-N amino hydrogen carbonate Chemical compound NOC(O)=O JTXJZBMXQMTSQN-UHFFFAOYSA-N 0.000 description 1
230000001139 anti-pruritic effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000003908 antipruritic agent Substances 0.000 description 1
210000000436 anus Anatomy 0.000 description 1
238000005452 bending Methods 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000000560 biocompatible material Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229960000846 camphor Drugs 0.000 description 1
229930008380 camphor Natural products 0.000 description 1
DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 description 1
229940095758 cantharidin Drugs 0.000 description 1
229930008397 cantharidin Natural products 0.000 description 1
DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 description 1
210000001736 capillary Anatomy 0.000 description 1
229960002504 capsaicin Drugs 0.000 description 1
235000017663 capsaicin Nutrition 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000010339 dilation Effects 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000005670 electromagnetic radiation Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
229940011916 ethacrynate sodium Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000001508 eye Anatomy 0.000 description 1
230000001408 fungistatic effect Effects 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
229960003883 furosemide Drugs 0.000 description 1
230000004927 fusion Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229960003711 glyceryl trinitrate Drugs 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229960002773 hyaluronidase Drugs 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
230000008776 intercellular pathway Effects 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
239000003410 keratolytic agent Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
239000011133 lead Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000003754 machining Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
108010019084 mastoparan Proteins 0.000 description 1
MASXKPLGZRMBJF-MVSGICTGSA-N mastoparan Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O MASXKPLGZRMBJF-MVSGICTGSA-N 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000000155 melt Substances 0.000 description 1
239000001525 mentha piperita l. herb oil Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
239000008164 mustard oil Substances 0.000 description 1
210000001989 nasopharynx Anatomy 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
210000000944 nerve tissue Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000013307 optical fiber Substances 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
235000019477 peppermint oil Nutrition 0.000 description 1
239000012466 permeate Substances 0.000 description 1
210000003800 pharynx Anatomy 0.000 description 1
230000002165 photosensitisation Effects 0.000 description 1
239000003504 photosensitizing agent Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000002985 plastic film Substances 0.000 description 1
229920006255 plastic film Polymers 0.000 description 1
229920001610 polycaprolactone Polymers 0.000 description 1
239000004632 polycaprolactone Substances 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
238000005086 pumping Methods 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
150000003873 salicylate salts Chemical class 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
230000008591 skin barrier function Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000013024 sodium fluoride Nutrition 0.000 description 1
239000011775 sodium fluoride Substances 0.000 description 1
CWCSCNSKBSCYCS-UHFFFAOYSA-M sodium;2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetate Chemical compound [Na+].CCC(=C)C(=O)C1=CC=C(OCC([O-])=O)C(Cl)=C1Cl CWCSCNSKBSCYCS-UHFFFAOYSA-M 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
229960001322 trypsin Drugs 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
- A61B2010/008—Interstitial fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B2017/00743—Type of operation; Specification of treatment sites
- A61B2017/00747—Dermatology
- A61B2017/00765—Decreasing the barrier function of skin tissue by radiated energy, e.g. using ultrasound, using laser for skin perforation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis

Definitions

the invention relates generally to the monitoring of analytes in the body and the transdermal delivery of drugs to the body. More particularly, the invention relates to enhancing the rate of flux of a substance collected from or delivered to a biological tissue through the poration of the skin or other biological membrane and the application of a flux enhancer to the porated biological membrane.
one aspect of the present invention involves a method for enhancing the flux rate of a fluid through biological tissue.
the method generally comprises the delivering an effective amount of a flux enhancer into the tissue through at least one micropore in the tissue.
the flux enhancer is delivered to the micropore through any of a number of mechanisms, examples of which are described below.
the depth of poration and of application of the flux enhancer can also be adjusted to suit the desired application.
FIG. 3 is an enlarged diagram showing the delivery of a flux enhancer from a reservoir using a probe according to another embodiment of the present invention.
FIG. 4 is an exploded view showing a device for facilitating the poration of a biological membrane and the delivery of a flux enhancer according to the present invention.
ablation means the controlled removal of material which may include cells or other components comprising some portion of a biological membrane or tissue caused by any of the following: kinetic energy released when some or all of the vaporizable components of such material have been heated to the point that vaporization occurs and the resulting rapid expansion of volume due to this phase change causes this material, and possibly some adjacent material, to be removed from the ablation site; thermal, mechanical, or sonic decomposition of some or all of the tissue at the poration site.
flux enhancer means any material that increases the rate of flow of a fluid through a biological tissue or membrane by any mechanism.
One such poration technique employs a heated probe, which is used to form one or more micropores of a selected depth in a biological tissue or membrane.
the heated probe is useful in the embodiments shown in FIGs. 2 and 3.
a heated probe can deliver sufficient energy into or through the hydrated viable tissue layers beneath the outer layer of the biological membrane so that the poration process can continue into the tissue to a selected depth, penetrating through deeper layers including, e.g., in the case of the skin, through the epidermis, the dermis, and into the subcutaneous layers below if desired.
the substrate layer 102 is preferably made of bio-compatible material, such as polycaprolactone or celluloseacetate which are commercially available.
the energy absorbing layer 104 is capable of absorbing energy received from an external source, such as a laser or other source of focused optical energy, converting that energy to heat, and transferring that heat to a target portion of the tissue to form at least one micropore by ablation.
the energy absorbing layer 104 comprises a dye layer, which can be formed of any energy absorbing material reactive with the external energy source, or of a non-absorbing substrate having an absorbing material applied thereon.
the devices described herein are constructed such that the entire drug reservoir, poration elements, and optionally controlling circuitry and power source can 0 be contained in a cone-time-use package approximately the size of a pocket watch or smaller This platform is suitable for applications such as post-operative delivery of 19 pain killers or other acute treatment regimens for which a controllable transdermal delivery system would be useful.

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Surgery (AREA)
Biomedical Technology (AREA)
Engineering & Computer Science (AREA)
Pathology (AREA)
Hematology (AREA)
Biophysics (AREA)
Medical Informatics (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Media Introduction/Drainage Providing Device (AREA)
Surgical Instruments (AREA)
External Artificial Organs (AREA)
Medicinal Preparation (AREA)
Infusion, Injection, And Reservoir Apparatuses (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP99911120A 1998-03-06 1999-03-05 Vorrichtung zur erhöhung der flüssigkeitsdurchflussgeschwindigkeit in einem biologischen gewebe mit mikroporen Expired - Lifetime EP1059939B1 (de)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
DK99911120T DK1059939T3 (da)	1998-03-06	1999-03-05	Apparat til at foröge gennemströmningshastigheder af et fluidum i et biologisk væv med mikro-porer

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US09/036,053 US6173202B1 (en)	1998-03-06	1998-03-06	Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue
US36053		1998-03-06
PCT/US1999/004798 WO1999044637A1 (en)	1998-03-06	1999-03-05	Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue

Publications (2)

Publication Number	Publication Date
EP1059939A1 true EP1059939A1 (de)	2000-12-20
EP1059939B1 EP1059939B1 (de)	2004-08-11

Family

ID=21886346

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP99911120A Expired - Lifetime EP1059939B1 (de)	1998-03-06	1999-03-05	Vorrichtung zur erhöhung der flüssigkeitsdurchflussgeschwindigkeit in einem biologischen gewebe mit mikroporen

Country Status (10)

Country	Link
US (2)	US6173202B1 (de)
EP (1)	EP1059939B1 (de)
JP (3)	JP2002505304A (de)
AT (1)	ATE273024T1 (de)
AU (1)	AU747794B2 (de)
CA (2)	CA2329167C (de)
DE (1)	DE69919335T2 (de)
DK (1)	DK1059939T3 (de)
ES (1)	ES2226353T3 (de)
WO (1)	WO1999044637A1 (de)

Families Citing this family (201)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6797276B1 (en)	1996-11-14	2004-09-28	The United States Of America As Represented By The Secretary Of The Army	Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en) *	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
US20060002949A1 (en) *	1996-11-14	2006-01-05	Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc.	Transcutaneous immunization without heterologous adjuvant
US20060002959A1 (en) *	1996-11-14	2006-01-05	Government Of The United States	Skin-sctive adjuvants for transcutaneous immuization
US7204832B2 (en)	1996-12-02	2007-04-17	Pálomar Medical Technologies, Inc.	Cooling system for a photo cosmetic device
US6517532B1 (en)	1997-05-15	2003-02-11	Palomar Medical Technologies, Inc.	Light energy delivery head
US8182473B2 (en) *	1999-01-08	2012-05-22	Palomar Medical Technologies	Cooling system for a photocosmetic device
US20060149343A1 (en) *	1996-12-02	2006-07-06	Palomar Medical Technologies, Inc.	Cooling system for a photocosmetic device
US6527716B1 (en)	1997-12-30	2003-03-04	Altea Technologies, Inc.	Microporation of tissue for delivery of bioactive agents
EP1433430A3 (de)	1997-05-15	2004-11-10	Palomar Medical Technologies, Inc.	Verfahren und Gerät zur Hautbehandlung
US7981112B1 (en) *	1997-08-12	2011-07-19	Joseph Neev	Home use device and methods for treating skin conditions
US8313480B2 (en) *	2004-10-02	2012-11-20	Joseph Neev	Device and method for treating skin disorders with thermal energy
US20040258703A1 (en) *	1997-11-14	2004-12-23	The Government Of The Us, As Represented By The Secretary Of The Army	Skin-active adjuvants for transcutaneous immunization
US6173202B1 (en) *	1998-03-06	2001-01-09	Spectrx, Inc.	Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue
CA2323479A1 (en)	1998-03-12	1999-09-16	Palomar Medical Technologies, Inc.	System for electromagnetic radiation of the skin
US6391005B1 (en)	1998-03-30	2002-05-21	Agilent Technologies, Inc.	Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
AU742552B2 (en)	1998-06-24	2002-01-03	Transderm Technologies Llc	Non-invasive transdermal detection of analytes
EP1987854A1 (de)	1998-07-14	2008-11-05	Altea Therapeutics Corporation	Transdermale Transportvorrichtung zum kontrollierten Entfernen von biologischen Membranen durch pyrotechnische Ladung
US6059820A (en)	1998-10-16	2000-05-09	Paradigm Medical Corporation	Tissue cooling rod for laser surgery
US6611706B2 (en)	1998-11-09	2003-08-26	Transpharma Ltd.	Monopolar and bipolar current application for transdermal drug delivery and analyte extraction
US6708060B1 (en) *	1998-11-09	2004-03-16	Transpharma Ltd.	Handheld apparatus and method for transdermal drug delivery and analyte extraction
US6148232A (en)	1998-11-09	2000-11-14	Elecsys Ltd.	Transdermal drug delivery and analyte extraction
US6597946B2 (en)	1998-11-09	2003-07-22	Transpharma Ltd.	Electronic card for transdermal drug delivery and analyte extraction
WO2000061184A2 (en) *	1999-04-08	2000-10-19	Glenn Gregory M	Dry formulation for transcutaneous immunization
US6334851B1 (en) *	1999-05-10	2002-01-01	Microfab Technologies, Inc.	Method for collecting interstitial fluid from the skin
US6692456B1 (en)	1999-06-08	2004-02-17	Altea Therapeutics Corporation	Apparatus for microporation of biological membranes using thin film tissue interface devices, and method therefor
US6685699B1 (en) *	1999-06-09	2004-02-03	Spectrx, Inc.	Self-removing energy absorbing structure for thermal tissue ablation
US20030078499A1 (en) *	1999-08-12	2003-04-24	Eppstein Jonathan A.	Microporation of tissue for delivery of bioactive agents
US6835184B1 (en)	1999-09-24	2004-12-28	Becton, Dickinson And Company	Method and device for abrading skin
AU784423B2 (en) *	2000-01-25	2006-03-30	General Hospital Corporation, The	Method and apparatus for medical treatment utilizing long duration electromagnetic radiation
WO2001076553A2 (en) *	2000-04-06	2001-10-18	Sontra Medical, Inc.	Method and device for enhanced transdermal drug delivery
US20040005349A1 (en) *	2000-05-12	2004-01-08	Joseph Neev	Opto-thermal material modification
US6595947B1 (en)	2000-05-22	2003-07-22	Becton, Dickinson And Company	Topical delivery of vaccines
IL155097A0 (en)	2000-09-28	2003-10-31	Nanocyte Inc	Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US7632522B2 (en)	2000-09-28	2009-12-15	Nanocyte Inc.	Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US6882884B1 (en)	2000-10-13	2005-04-19	Soundskin, L.L.C.	Process for the stimulation of production of extracellular dermal proteins in human tissue
US8641644B2 (en)	2000-11-21	2014-02-04	Sanofi-Aventis Deutschland Gmbh	Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
CN103251453A (zh) *	2000-12-28	2013-08-21	帕洛玛医疗技术有限公司	用于皮肤的emr治疗处理的方法和装置
US20020173780A1 (en) *	2001-03-02	2002-11-21	Altshuler Gregory B.	Apparatus and method for photocosmetic and photodermatological treatment
US20080183162A1 (en) *	2000-12-28	2008-07-31	Palomar Medical Technologies, Inc.	Methods And Devices For Fractional Ablation Of Tissue
EP1372708B1 (de) *	2001-02-13	2008-06-18	GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY	Impstoffe zur transkutanen immunisierung gegen reisediarrhö
US6888319B2 (en) *	2001-03-01	2005-05-03	Palomar Medical Technologies, Inc.	Flashlamp drive circuit
WO2003039620A2 (en)	2001-05-17	2003-05-15	Transpharma Medical Ltd.	Integrated transdermal drug delivery system
US6855117B2 (en)	2001-08-01	2005-02-15	Johnson & Johnson Consumer Companies, Inc.	Method of treating the skin of a subject
US6790179B2 (en)	2001-08-01	2004-09-14	Johnson & Johnson Consumer Companies, Inc.	Method of examining and diagnosing skin health
US6840910B2 (en)	2001-08-01	2005-01-11	Johnson & Johnson Consumer Companies, Inc.	Method of distributing skin care products
ES2268050T3 (es) *	2001-06-08	2007-03-16	Becton, Dickinson And Company	Dispositivo para manipular un conjunto de agujas o abrasion.
US7981056B2 (en)	2002-04-19	2011-07-19	Pelikan Technologies, Inc.	Methods and apparatus for lancet actuation
ATE485766T1 (de)	2001-06-12	2010-11-15	Pelikan Technologies Inc	Elektrisches betätigungselement für eine lanzette
EP1404232B1 (de)	2001-06-12	2009-12-02	Pelikan Technologies Inc.	Gerät und verfahren zur entnahme von blutproben
JP4209767B2 (ja)	2001-06-12	2009-01-14	ペリカンテクノロジーズインコーポレイテッド	皮膚の性状の一時的変化に対する適応手段を備えた自動最適化形切開器具
US9226699B2 (en)	2002-04-19	2016-01-05	Sanofi-Aventis Deutschland Gmbh	Body fluid sampling module with a continuous compression tissue interface surface
US8337419B2 (en)	2002-04-19	2012-12-25	Sanofi-Aventis Deutschland Gmbh	Tissue penetration device
AU2002348683A1 (en)	2001-06-12	2002-12-23	Pelikan Technologies, Inc.	Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US9427532B2 (en)	2001-06-12	2016-08-30	Sanofi-Aventis Deutschland Gmbh	Tissue penetration device
US7025774B2 (en)	2001-06-12	2006-04-11	Pelikan Technologies, Inc.	Tissue penetration device
US9795747B2 (en)	2010-06-02	2017-10-24	Sanofi-Aventis Deutschland Gmbh	Methods and apparatus for lancet actuation
EP1439870B1 (de) *	2001-10-29	2009-01-14	Becton, Dickinson and Company	Vorrichtung für die abgabe einer substanz
US20040120964A1 (en) *	2001-10-29	2004-06-24	Mikszta John A.	Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
US20040147984A1 (en) *	2001-11-29	2004-07-29	Palomar Medical Technologies, Inc.	Methods and apparatus for delivering low power optical treatments
US20050049582A1 (en) *	2001-12-12	2005-03-03	Debenedictis Leonard C.	Method and apparatus for fractional photo therapy of skin
US20040082940A1 (en) *	2002-10-22	2004-04-29	Michael Black	Dermatological apparatus and method
US20030216719A1 (en) *	2001-12-12	2003-11-20	Len Debenedictis	Method and apparatus for treating skin using patterns of optical energy
US7540869B2 (en) *	2001-12-27	2009-06-02	Palomar Medical Technologies, Inc.	Method and apparatus for improved vascular related treatment
US20040073175A1 (en) *	2002-01-07	2004-04-15	Jacobson James D.	Infusion system
WO2003077970A2 (en)	2002-03-11	2003-09-25	Altea Therapeutics Corporation	Transdermal integrated actuator device, methods of making and using same
US8116860B2 (en)	2002-03-11	2012-02-14	Altea Therapeutics Corporation	Transdermal porator and patch system and method for using same
US9918665B2 (en)	2002-03-11	2018-03-20	Nitto Denko Corporation	Transdermal porator and patch system and method for using same
US7611723B2 (en)	2002-03-26	2009-11-03	Nanocyte Inc.	Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US7648468B2 (en)	2002-04-19	2010-01-19	Pelikon Technologies, Inc.	Method and apparatus for penetrating tissue
US7892183B2 (en)	2002-04-19	2011-02-22	Pelikan Technologies, Inc.	Method and apparatus for body fluid sampling and analyte sensing
US8372016B2 (en)	2002-04-19	2013-02-12	Sanofi-Aventis Deutschland Gmbh	Method and apparatus for body fluid sampling and analyte sensing
US7524293B2 (en)	2002-04-19	2009-04-28	Pelikan Technologies, Inc.	Method and apparatus for penetrating tissue
US9248267B2 (en)	2002-04-19	2016-02-02	Sanofi-Aventis Deustchland Gmbh	Tissue penetration device
US7410468B2 (en)	2002-04-19	2008-08-12	Pelikan Technologies, Inc.	Method and apparatus for penetrating tissue
US7976476B2 (en)	2002-04-19	2011-07-12	Pelikan Technologies, Inc.	Device and method for variable speed lancet
AU2003226605A1 (en) *	2002-04-19	2003-11-03	Transpharma Medical Ltd.	Handheld transdermal drug delivery and analyte extraction
US7717863B2 (en)	2002-04-19	2010-05-18	Pelikan Technologies, Inc.	Method and apparatus for penetrating tissue
US7141058B2 (en)	2002-04-19	2006-11-28	Pelikan Technologies, Inc.	Method and apparatus for a body fluid sampling device using illumination
US7175642B2 (en)	2002-04-19	2007-02-13	Pelikan Technologies, Inc.	Methods and apparatus for lancet actuation
US7331931B2 (en)	2002-04-19	2008-02-19	Pelikan Technologies, Inc.	Method and apparatus for penetrating tissue
US7244265B2 (en)	2002-04-19	2007-07-17	Pelikan Technologies, Inc.	Method and apparatus for penetrating tissue
US7674232B2 (en)	2002-04-19	2010-03-09	Pelikan Technologies, Inc.	Method and apparatus for penetrating tissue
US7491178B2 (en)	2002-04-19	2009-02-17	Pelikan Technologies, Inc.	Method and apparatus for penetrating tissue
US7291117B2 (en)	2002-04-19	2007-11-06	Pelikan Technologies, Inc.	Method and apparatus for penetrating tissue
US7901362B2 (en)	2002-04-19	2011-03-08	Pelikan Technologies, Inc.	Method and apparatus for penetrating tissue
US9314194B2 (en)	2002-04-19	2016-04-19	Sanofi-Aventis Deutschland Gmbh	Tissue penetration device
US9795334B2 (en)	2002-04-19	2017-10-24	Sanofi-Aventis Deutschland Gmbh	Method and apparatus for penetrating tissue
US8221334B2 (en)	2002-04-19	2012-07-17	Sanofi-Aventis Deutschland Gmbh	Method and apparatus for penetrating tissue
US7374544B2 (en)	2002-04-19	2008-05-20	Pelikan Technologies, Inc.	Method and apparatus for penetrating tissue
US8579831B2 (en)	2002-04-19	2013-11-12	Sanofi-Aventis Deutschland Gmbh	Method and apparatus for penetrating tissue
US7229458B2 (en)	2002-04-19	2007-06-12	Pelikan Technologies, Inc.	Method and apparatus for penetrating tissue
US7547287B2 (en)	2002-04-19	2009-06-16	Pelikan Technologies, Inc.	Method and apparatus for penetrating tissue
US7297122B2 (en)	2002-04-19	2007-11-20	Pelikan Technologies, Inc.	Method and apparatus for penetrating tissue
US7713214B2 (en)	2002-04-19	2010-05-11	Pelikan Technologies, Inc.	Method and apparatus for a multi-use body fluid sampling device with optical analyte sensing
US8784335B2 (en)	2002-04-19	2014-07-22	Sanofi-Aventis Deutschland Gmbh	Body fluid sampling device with a capacitive sensor
US8702624B2 (en)	2006-09-29	2014-04-22	Sanofi-Aventis Deutschland Gmbh	Analyte measurement device with a single shot actuator
US7909778B2 (en)	2002-04-19	2011-03-22	Pelikan Technologies, Inc.	Method and apparatus for penetrating tissue
WO2003088824A2 (en)	2002-04-19	2003-10-30	Pelikan Technologies, Inc.	Device and method for variable speed lancet
US7563232B2 (en)	2002-04-19	2009-07-21	Pelikan Technologies, Inc.	Method and apparatus for penetrating tissue
US7371247B2 (en)	2002-04-19	2008-05-13	Pelikan Technologies, Inc	Method and apparatus for penetrating tissue
US7485128B2 (en)	2002-04-19	2009-02-03	Pelikan Technologies, Inc.	Method and apparatus for penetrating tissue
US7232451B2 (en)	2002-04-19	2007-06-19	Pelikan Technologies, Inc.	Method and apparatus for penetrating tissue
US20070239143A1 (en) *	2006-03-10	2007-10-11	Palomar Medical Technologies, Inc.	Photocosmetic device
WO2004000150A1 (en) *	2002-06-19	2003-12-31	Palomar Medical Technologies, Inc.	Method and apparatus for photothermal treatment of tissue at depth
CN1329008C (zh) *	2002-06-19	2007-08-01	帕洛玛医疗技术公司	用于处理皮肤和皮下情况的设备
US20070219605A1 (en) *	2006-03-20	2007-09-20	Palomar Medical Technologies, Inc.	Treatment of tissue volume with radiant energy
US20070213792A1 (en) *	2002-10-07	2007-09-13	Palomar Medical Technologies, Inc.	Treatment Of Tissue Volume With Radiant Energy
EP1558339A1 (de) *	2002-10-07	2005-08-03	Palomar Medical Technologies, Inc.	Vorrichtung zur photobiostimulation
EP2522293A2 (de) *	2002-10-23	2012-11-14	Palomar Medical Technologies, Inc.	Photobehandlungsvorrichtung zur Verwendung mit Kühlmitteln und topischen Substanzen
US20050049522A1 (en) *	2002-10-30	2005-03-03	Allen John J	Method of lancing skin for the extraction of blood
US8133505B2 (en) *	2002-10-31	2012-03-13	Transpharma Medical Ltd.	Transdermal delivery system for dried particulate or lyophilized medications
IL152574A (en) *	2002-10-31	2009-09-22	Transpharma Medical Ltd	A system for passing through the skin of dry items or dried medicines
US7662404B2 (en) *	2002-10-31	2010-02-16	Transpharma Medical Ltd.	Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides
IL152573A (en) *	2002-10-31	2009-11-18	Transpharma Medical Ltd	A system for the transmission through the skin of a medical preparation against vomiting and nausea
IL152575A (en) *	2002-10-31	2008-12-29	Transpharma Medical Ltd	A skin-to-skin transmission system of water-insoluble drugs
US7383084B2 (en) *	2002-10-31	2008-06-03	Transpharma Medical Ltd.	Transdermal delivery system for dried particulate or lyophilized medications
AU2003301111A1 (en) *	2002-12-20	2004-07-22	Palomar Medical Technologies, Inc.	Apparatus for light treatment of acne and other disorders of follicles
US8574895B2 (en)	2002-12-30	2013-11-05	Sanofi-Aventis Deutschland Gmbh	Method and apparatus using optical techniques to measure analyte levels
WO2004073537A2 (en) *	2003-02-19	2004-09-02	Palomar Medical Technologies, Inc.	Method and apparatus for treating pseudofolliculitis barbae
AU2004226378A1 (en) *	2003-03-27	2004-10-14	The General Hospital Corporation	Method and apparatus for dermatological treatment and fractional skin resurfacing
US7473264B2 (en) *	2003-03-28	2009-01-06	Lifescan, Inc.	Integrated lance and strip for analyte measurement
US20040193202A1 (en) *	2003-03-28	2004-09-30	Allen John J.	Integrated lance and strip for analyte measurement
US20040193072A1 (en) *	2003-03-28	2004-09-30	Allen John J.	Method of analyte measurement using integrated lance and strip
EP2238892A3 (de)	2003-05-30	2011-02-09	Pelikan Technologies Inc.	Vorrichtung zur Entnahme von Körperflüssigkeit
ES2490740T3 (es)	2003-06-06	2014-09-04	Sanofi-Aventis Deutschland Gmbh	Aparato para toma de muestras de fluido sanguíneo y detección de analitos
WO2006001797A1 (en)	2004-06-14	2006-01-05	Pelikan Technologies, Inc.	Low pain penetrating
US7604592B2 (en)	2003-06-13	2009-10-20	Pelikan Technologies, Inc.	Method and apparatus for a point of care device
JP5015594B2 (ja) *	2003-06-23	2012-08-29	トランスファーマメディカルリミテッド	化粧剤用経皮送達システム
IL156789A0 (en) *	2003-07-06	2004-02-08		Adapter for multi-element contact-probe
EP1671096A4 (de)	2003-09-29	2009-09-16	Pelikan Technologies Inc	Verfahren und apparatur für eine verbesserte probeneinfangvorrichtung
WO2005037095A1 (en)	2003-10-14	2005-04-28	Pelikan Technologies, Inc.	Method and apparatus for a variable user interface
US8016811B2 (en)	2003-10-24	2011-09-13	Altea Therapeutics Corporation	Method for transdermal delivery of permeant substances
US7299082B2 (en)	2003-10-31	2007-11-20	Abbott Diabetes Care, Inc.	Method of calibrating an analyte-measurement device, and associated methods, devices and systems
IL159273A0 (en) *	2003-12-09	2004-06-01	Transpharma Medical Ltd	Transdermal delivery system for sustained release of polypeptides
US8668656B2 (en)	2003-12-31	2014-03-11	Sanofi-Aventis Deutschland Gmbh	Method and apparatus for improving fluidic flow and sample capture
WO2005065565A1 (en) *	2003-12-31	2005-07-21	Palomar Medical Technologies, Inc.	Dermatological treatment with vusualization
US7822454B1 (en)	2005-01-03	2010-10-26	Pelikan Technologies, Inc.	Fluid sampling device with improved analyte detecting member configuration
US7699964B2 (en) *	2004-02-09	2010-04-20	Abbott Diabetes Care Inc.	Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US8165651B2 (en) *	2004-02-09	2012-04-24	Abbott Diabetes Care Inc.	Analyte sensor, and associated system and method employing a catalytic agent
US20050187525A1 (en) *	2004-02-19	2005-08-25	Hilgers Michael E.	Devices and methods for extracting bodily fluid
EP1742588B1 (de)	2004-04-01	2016-10-19	The General Hospital Corporation	Gerät für die dermatologische behandlung und gewebeumformung
US20080132886A1 (en) *	2004-04-09	2008-06-05	Palomar Medical Technologies, Inc.	Use of fractional emr technology on incisions and internal tissues
AU2005232581A1 (en) *	2004-04-09	2005-10-27	Palomar Medical Technologies, Inc.	Emr treated islets
US8828203B2 (en)	2004-05-20	2014-09-09	Sanofi-Aventis Deutschland Gmbh	Printable hydrogels for biosensors
US9775553B2 (en)	2004-06-03	2017-10-03	Sanofi-Aventis Deutschland Gmbh	Method and apparatus for a fluid sampling device
US7413572B2 (en) *	2004-06-14	2008-08-19	Reliant Technologies, Inc.	Adaptive control of optical pulses for laser medicine
US20050284757A1 (en) *	2004-06-29	2005-12-29	Allen John J	Analyte measuring system which prevents the reuse of a test strip
US20050284773A1 (en) *	2004-06-29	2005-12-29	Allen John J	Method of preventing reuse in an analyte measuring system
US20060024722A1 (en)	2004-07-30	2006-02-02	Mark Fischer-Colbrie	Samples for detection of oncofetal fibronectin and uses thereof
US20060253176A1 (en) *	2005-02-18	2006-11-09	Palomar Medical Technologies, Inc.	Dermatological treatment device with deflector optic
AU2006214028A1 (en) *	2005-02-18	2006-08-24	Palomar Medical Technologies, Inc.	Dermatological treatment device
US7704743B2 (en) *	2005-03-30	2010-04-27	Georgia Tech Research Corporation	Electrosonic cell manipulation device and method of use thereof
US8834862B2 (en)	2005-04-19	2014-09-16	Nanocyte Inc.	Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
US7856985B2 (en)	2005-04-22	2010-12-28	Cynosure, Inc.	Method of treatment body tissue using a non-uniform laser beam
CA2610757A1 (en) *	2005-06-10	2006-12-14	Transpharma Medical, Ltd.	Patch for transdermal drug delivery
AU2006292526A1 (en)	2005-09-15	2007-03-29	Palomar Medical Technologies, Inc.	Skin optical characterization device
US20090036795A1 (en) *	2005-09-26	2009-02-05	Koninklijke Philips Electronics, N.V.	Substance sampling and/or substance delivery via skin
WO2007095183A2 (en) *	2006-02-13	2007-08-23	Reliant Technologies, Inc.	Laser system for treatment of skin laxity
US20070194717A1 (en) *	2006-02-17	2007-08-23	Palomar Medical Technologies, Inc.	Lamp for use in a tissue treatment device
US7885698B2 (en) *	2006-02-28	2011-02-08	Abbott Diabetes Care Inc.	Method and system for providing continuous calibration of implantable analyte sensors
WO2007117580A2 (en) *	2006-04-06	2007-10-18	Palomar Medical Technologies, Inc.	Apparatus and method for skin treatment with compression and decompression
US20080234626A1 (en) *	2006-04-26	2008-09-25	Chelak Todd M	Multi-stage microporation device
US7586957B2 (en) *	2006-08-02	2009-09-08	Cynosure, Inc	Picosecond laser apparatus and methods for its operation and use
US20100004582A1 (en) *	2006-10-25	2010-01-07	Pantec Biosolutions Ag	Wide-Area Parasystemic Treatment of Skin Related Conditions
US20080161782A1 (en) *	2006-10-26	2008-07-03	Reliant Technologies, Inc.	Micropore delivery of active substances
US20080208179A1 (en) *	2006-10-26	2008-08-28	Reliant Technologies, Inc.	Methods of increasing skin permeability by treatment with electromagnetic radiation
US20080161666A1 (en) *	2006-12-29	2008-07-03	Abbott Diabetes Care, Inc.	Analyte devices and methods
EP2120825B8 (de)	2007-01-22	2017-05-24	Nitto Denko Corporation	Transdermaler porator und patch-system
US20080186591A1 (en) *	2007-02-01	2008-08-07	Palomar Medical Technologies, Inc.	Dermatological device having a zoom lens system
EP2131900B1 (de) *	2007-03-19	2018-05-30	Insuline Medical Ltd.	Arzneimittelabgabevorrichtung
US8622991B2 (en) *	2007-03-19	2014-01-07	Insuline Medical Ltd.	Method and device for drug delivery
EP2158516A1 (de) *	2007-06-08	2010-03-03	Cynosure, Inc.	Überwachung von thermischer operation
JP5466161B2 (ja) *	2007-10-09	2014-04-09	トランスファーマメディカルリミテッド	磁気的なパッチ連結物
CA2696227A1 (en) *	2007-10-17	2009-04-23	Transpharma Medical Ltd.	Dissolution rate verification
EP2211918B1 (de) *	2007-10-29	2017-10-18	Syneron Medical Ltd.	Vertikale pflastertrocknung
WO2009072108A2 (en)	2007-12-05	2009-06-11	Syneron Medical Ltd.	A disposable electromagnetic energy applicator and method of using it
CN101938951B (zh) *	2008-01-17	2013-06-12	赛诺龙医疗公司	用于个人使用的毛发去除装置及使用该装置的方法
JP2011509791A (ja) *	2008-01-24	2011-03-31	シネロンメディカルリミテッド	脂肪組織治療の機器、装置および方法
WO2009124095A1 (en) *	2008-03-31	2009-10-08	Abbott Diabetes Care Inc.	Shallow implantable analyte sensor with rapid physiological response
US9387033B2 (en) *	2008-08-28	2016-07-12	Roche Diabetes Care, Inc.	Device and method for enhanced subcutaneous insulin absorption
ES2412783T3 (es) *	2008-09-21	2013-07-12	Syneron Medical Ltd.	Un método y aparato para el tratamiento personal de la piel
US9375169B2 (en)	2009-01-30	2016-06-28	Sanofi-Aventis Deutschland Gmbh	Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US8606366B2 (en)	2009-02-18	2013-12-10	Syneron Medical Ltd.	Skin treatment apparatus for personal use and method for using same
US9919168B2 (en)	2009-07-23	2018-03-20	Palomar Medical Technologies, Inc.	Method for improvement of cellulite appearance
US8965476B2 (en)	2010-04-16	2015-02-24	Sanofi-Aventis Deutschland Gmbh	Tissue penetration device
US20120016320A1 (en) *	2010-07-13	2012-01-19	Lin Michael T	Method and Device for Liquid Delivery
EP2790684B1 (de)	2011-12-16	2016-10-12	3M Innovative Properties Company	Faltbarer zusammengesetzter haftverband
KR102136901B1 (ko)	2012-04-18	2020-07-22	싸이노슈어, 엘엘씨	피코초 레이저 장치 및 그를 사용한 표적 조직의 치료 방법
EP2973894A2 (de)	2013-03-15	2016-01-20	Cynosure, Inc.	Optische picosekunden-strahlungssysteme und verfahren zur verwendung
AU2014374361B9 (en)	2013-12-31	2019-07-04	Abbott Diabetes Care Inc.	Self-powered analyte sensor and devices using the same
US11178823B2 (en)	2014-04-07	2021-11-23	Premier Citrus Apz, Llc	Systems and methods for using light energy to facilitate penetration of substances in plants
US9265260B1 (en)	2014-04-07	2016-02-23	Gpd Technologies Llc	Systems and methods for using light energy to facilitate penetration of substances in plants
US10278334B2 (en)	2014-04-07	2019-05-07	Premier Citrus Apz, Llc	Systems and methods for delivering nucleic acids to a plant
WO2016054079A1 (en)	2014-09-29	2016-04-07	Zyomed Corp.	Systems and methods for blood glucose and other analyte detection and measurement using collision computing
WO2016054576A1 (en)	2014-10-02	2016-04-07	Translogic Corporation	Multiple dock station for pneumatic transport system
US11191278B2 (en)	2016-03-25	2021-12-07	Premier Citrus Apz, Llc	Systems and methods for delivering nucleic acids to a plant
US9554738B1 (en)	2016-03-30	2017-01-31	Zyomed Corp.	Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing
LT3245988T (lt)	2016-05-18	2024-02-12	Sonikure Holdings Limited	Ultragarsu pagerinto transsklerinio vaistų pristatymo sistema
CN112042066A (zh)	2018-02-26	2020-12-04	赛诺秀股份有限公司	调q倾腔亚纳秒激光器
WO2020077246A1 (en) *	2018-10-12	2020-04-16	Immunolight, Llc	Methods, devices, and compositions for measuring and inducing cell-to-cell communication, and therapeutic uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3964482A (en)	1971-05-17	1976-06-22	Alza Corporation	Drug delivery device
US4605670A (en)	1984-02-01	1986-08-12	Nitto Electric Industrial Co., Ltd.	Method for percutaneously administering metoclopramide
US4775361A (en)	1986-04-10	1988-10-04	The General Hospital Corporation	Controlled removal of human stratum corneum by pulsed laser to enhance percutaneous transport
DE68925030T2 (de)	1988-01-21	1996-07-25	Massachusetts Inst Technology	Molekültransport durch gewebe mit der verwendung von elektroporation.
US5088977A (en) *	1988-12-21	1992-02-18	Drug Delivery Systems Inc.	Electrical transdermal drug applicator with counteractor and method of drug delivery
JP2703035B2 (ja) *	1989-02-28	1998-01-26	久光製薬株式会社	イオントフォレーゼ用デバイス
EP0429842B1 (de)	1989-10-27	1996-08-28	Korea Research Institute Of Chemical Technology	Vorrichtung zur transdermalen Applikation von Protein- oder Peptid-Medikamenten
US5016615A (en)	1990-02-20	1991-05-21	Riverside Research Institute	Local application of medication with ultrasound
US5115805A (en)	1990-02-23	1992-05-26	Cygnus Therapeutic Systems	Ultrasound-enhanced delivery of materials into and through the skin
US5231975A (en)	1990-02-23	1993-08-03	Cygnus Therapeutic Systems	Ultrasound-enhanced delivery of materials into and through the skin
US5527288A (en) *	1990-12-13	1996-06-18	Elan Medical Technologies Limited	Intradermal drug delivery device and method for intradermal delivery of drugs
US5215520A (en)	1991-09-17	1993-06-01	Centre Internationale De Recherches Dermatologiques Galderma (C.I.R.D. Galderma)	Method for delivering an active substance topically or percutaneously
US5713845A (en) *	1991-10-29	1998-02-03	Thermolase Corporation	Laser assisted drug delivery
US5246437A (en)	1992-04-10	1993-09-21	Abela George S	Cell treatment apparatus and method
US5643252A (en)	1992-10-28	1997-07-01	Venisect, Inc.	Laser perforator
US5427585A (en) *	1993-03-29	1995-06-27	Bettinger; David S.	On-demand iontophoretic system
US5458140A (en)	1993-11-15	1995-10-17	Non-Invasive Monitoring Company (Nimco)	Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5445611A (en)	1993-12-08	1995-08-29	Non-Invasive Monitoring Company (Nimco)	Enhancement of transdermal delivery with ultrasound and chemical enhancers
US5885211A (en)	1993-11-15	1999-03-23	Spectrix, Inc.	Microporation of human skin for monitoring the concentration of an analyte
US5947921A (en) *	1995-12-18	1999-09-07	Massachusetts Institute Of Technology	Chemical and physical enhancers and ultrasound for transdermal drug delivery
CA2200984A1 (en)	1995-07-25	1997-02-13	Samir S. Mitragotri	Enhanced transdermal transfer using ultrasound
GB2307414B (en)	1995-08-29	1998-03-11	Spectrx Inc	Microporation of human skin for drug delivery and monitoring applications
WO1998000193A1 (en)	1996-07-03	1998-01-08	Altea Technologies, Inc.	Multiple mechanical microporation of skin or mucosa
EP0952850A2 (de)	1996-12-31	1999-11-03	Altea Technologies, Inc.	Mikroporation von gewebe zur bioaktive-mittel-abgabe
US5999847A (en) *	1997-10-21	1999-12-07	Elstrom; John A.	Apparatus and method for delivery of surgical and therapeutic agents
US6173202B1 (en) *	1998-03-06	2001-01-09	Spectrx, Inc.	Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue
US6022316A (en)	1998-03-06	2000-02-08	Spectrx, Inc.	Apparatus and method for electroporation of microporated tissue for enhancing flux rates for monitoring and delivery applications

1998
- 1998-03-06 US US09/036,053 patent/US6173202B1/en not_active Expired - Lifetime
1999
- 1999-03-05 DK DK99911120T patent/DK1059939T3/da active
- 1999-03-05 CA CA002329167A patent/CA2329167C/en not_active Expired - Lifetime
- 1999-03-05 DE DE69919335T patent/DE69919335T2/de not_active Expired - Lifetime
- 1999-03-05 CA CA2637760A patent/CA2637760C/en not_active Expired - Lifetime
- 1999-03-05 AT AT99911120T patent/ATE273024T1/de not_active IP Right Cessation
- 1999-03-05 JP JP2000534238A patent/JP2002505304A/ja not_active Withdrawn
- 1999-03-05 ES ES99911120T patent/ES2226353T3/es not_active Expired - Lifetime
- 1999-03-05 EP EP99911120A patent/EP1059939B1/de not_active Expired - Lifetime
- 1999-03-05 WO PCT/US1999/004798 patent/WO1999044637A1/en not_active Ceased
- 1999-03-05 AU AU29840/99A patent/AU747794B2/en not_active Ceased
2000
- 2000-11-22 US US09/718,442 patent/US6508785B1/en not_active Expired - Lifetime
2007
- 2007-03-13 JP JP2007064243A patent/JP2007195999A/ja not_active Withdrawn
2010
- 2010-09-06 JP JP2010199420A patent/JP2011005283A/ja active Pending

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9944637A1 *

Also Published As

Publication number	Publication date
WO1999044637A1 (en)	1999-09-10
CA2329167C (en)	2008-11-18
JP2007195999A (ja)	2007-08-09
CA2637760C (en)	2015-01-06
JP2011005283A (ja)	2011-01-13
AU747794B2 (en)	2002-05-23
ES2226353T3 (es)	2005-03-16
US6173202B1 (en)	2001-01-09
DE69919335T2 (de)	2005-08-11
DE69919335D1 (de)	2004-09-16
JP2002505304A (ja)	2002-02-19
ATE273024T1 (de)	2004-08-15
AU2984099A (en)	1999-09-20
CA2329167A1 (en)	1999-09-10
DK1059939T3 (da)	2004-12-06
US6508785B1 (en)	2003-01-21
EP1059939B1 (de)	2004-08-11
CA2637760A1 (en)	1999-09-10

Legal Events

Date	Code	Title	Description
2000-11-03	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2000-12-20	17P	Request for examination filed	Effective date: 20000912
2000-12-20	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2003-05-02	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: ALTEA THERAPEUTICS CORPORATION Owner name: SPECTRX, INC.
2004-01-22	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2004-02-04	RTI1	Title (correction)	Free format text: APPARATUS FOR ENHANCING FLUX RATES OF A FLUID IN A MICROPORATED BIOLOGICAL TISSUE
2004-06-04	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2004-06-25	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2004-08-11	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2004-08-11	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040811 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040811
2004-08-11	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2004-08-13	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2004-09-08	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2004-09-16	REF	Corresponds to:	Ref document number: 69919335 Country of ref document: DE Date of ref document: 20040916 Kind code of ref document: P
2004-09-29	RAP2	Party data changed (patent owner data changed or rights of a patent transferred)	Owner name: ALTEA THERAPEUTICS CORPORATION Owner name: SPECTRX, INC.
2004-10-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: NV Representative=s name: AMMANN PATENTANWAELTE AG BERN
2004-11-11	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20041111
2004-11-30	REG	Reference to a national code	Ref country code: SE Ref legal event code: TRGR
2004-12-01	NLT2	Nl: modifications (of names), taken from the european patent patent bulletin	Owner name: ALTEA THERAPEUTICS CORPORATION
2004-12-06	REG	Reference to a national code	Ref country code: DK Ref legal event code: T3
2005-03-05	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050305 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20050305
2005-03-16	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2226353 Country of ref document: ES Kind code of ref document: T3
2005-03-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050331
2005-06-17	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2005-06-17	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2005-07-15	ET	Fr: translation filed
2005-08-03	26N	No opposition filed	Effective date: 20050512
2008-01-02	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050111
2014-04-25	REG	Reference to a national code	Ref country code: DE Ref legal event code: R082 Ref document number: 69919335 Country of ref document: DE Representative=s name: MUELLER SCHUPFNER & PARTNER PATENT- UND RECHTS, DE
2014-06-05	REG	Reference to a national code	Ref country code: DE Ref legal event code: R082 Ref document number: 69919335 Country of ref document: DE Representative=s name: MUELLER SCHUPFNER & PARTNER PATENT- UND RECHTS, DE Effective date: 20140425 Ref country code: DE Ref legal event code: R081 Ref document number: 69919335 Country of ref document: DE Owner name: NITTO DENKO CORPORATION, IBARAKI-SHI, JP Free format text: FORMER OWNER: ALTEA THERAPEUTICS CORP., TUCKER, GA., US Effective date: 20140425 Ref country code: DE Ref legal event code: R081 Ref document number: 69919335 Country of ref document: DE Owner name: NITTO DENKO CORPORATION, JP Free format text: FORMER OWNER: ALTEA THERAPEUTICS CORP., TUCKER, GA., US Effective date: 20140425 Ref country code: DE Ref legal event code: R081 Ref document number: 69919335 Country of ref document: DE Owner name: NITTO DENKO CORPORATION, JP Free format text: FORMER OWNER: ALTEA THERAPEUTICS CORP., TUCKER, US Effective date: 20140425
2014-10-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: PUE Owner name: NITTO DENKO CORPORATION, JP Free format text: FORMER OWNER: ALTEA THERAPEUTICS CORPORATION, US
2015-02-24	REG	Reference to a national code	Ref country code: DE Ref legal event code: R082 Ref document number: 69919335 Country of ref document: DE Representative=s name: MUELLER SCHUPFNER & PARTNER PATENT- UND RECHTS, DE
2015-03-04	REG	Reference to a national code	Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20150205 AND 20150211
2015-03-09	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 17
2015-04-02	REG	Reference to a national code	Ref country code: DE Ref legal event code: R082 Ref document number: 69919335 Country of ref document: DE Representative=s name: MUELLER SCHUPFNER & PARTNER PATENT- UND RECHTS, DE Effective date: 20150224 Ref country code: DE Ref legal event code: R081 Ref document number: 69919335 Country of ref document: DE Owner name: NITTO DENKO CORPORATION, IBARAKI-SHI, JP Free format text: FORMER OWNER: NITTO DENKO CORPORATION, TOKYO, JP Effective date: 20150224
2015-06-17	REG	Reference to a national code	Ref country code: NL Ref legal event code: TD Effective date: 20150611 Ref country code: NL Ref legal event code: SD Effective date: 20150611
2016-01-01	REG	Reference to a national code	Ref country code: FR Ref legal event code: GC Effective date: 20151018
2016-03-09	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 18
2016-04-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DK Payment date: 20160310 Year of fee payment: 18 Ref country code: CH Payment date: 20160311 Year of fee payment: 18 Ref country code: NL Payment date: 20160310 Year of fee payment: 18 Ref country code: IE Payment date: 20160309 Year of fee payment: 18 Ref country code: ES Payment date: 20160311 Year of fee payment: 18
2016-05-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: BE Payment date: 20160314 Year of fee payment: 18 Ref country code: SE Payment date: 20160311 Year of fee payment: 18
2016-08-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IT Payment date: 20160324 Year of fee payment: 18
2017-02-13	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 19
2017-10-23	REG	Reference to a national code	Ref country code: DK Ref legal event code: EBP Effective date: 20170331
2017-10-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL Ref country code: SE Ref legal event code: EUG
2017-11-08	REG	Reference to a national code	Ref country code: NL Ref legal event code: MM Effective date: 20170401
2017-11-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170306
2017-12-27	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2018-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170401
2018-02-23	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 20
2018-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170305 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170331 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170331 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170305
2018-03-07	REG	Reference to a national code	Ref country code: BE Ref legal event code: MM Effective date: 20170331
2018-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170331
2018-04-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20180228 Year of fee payment: 20 Ref country code: DE Payment date: 20180220 Year of fee payment: 20
2018-05-07	REG	Reference to a national code	Ref country code: ES Ref legal event code: FD2A Effective date: 20180507
2018-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170331
2018-05-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20180223 Year of fee payment: 20
2018-07-27	REG	Reference to a national code	Ref country code: FR Ref legal event code: GC Effective date: 20180622 Ref country code: FR Ref legal event code: AU Effective date: 20180622
2018-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170306
2018-08-03	REG	Reference to a national code	Ref country code: FR Ref legal event code: TP Owner name: NITTO DENKO CORPOARTION, JP Effective date: 20180629
2019-03-05	REG	Reference to a national code	Ref country code: DE Ref legal event code: R071 Ref document number: 69919335 Country of ref document: DE
2019-03-27	REG	Reference to a national code	Ref country code: GB Ref legal event code: PE20 Expiry date: 20190304
2019-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20190304

Publication	Publication Date	Title
AU747794B2 (en)	2002-05-23	Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue
US7758561B2 (en)	2010-07-20	Microporation of tissue for delivery of bioactive agents
EP1314400B1 (de)	2007-06-20	Mikroporation von Gewebe zur Verabreichung von bioaktiven Substanzen
US6527716B1 (en)	2003-03-04	Microporation of tissue for delivery of bioactive agents
JP3899427B2 (ja)	2007-03-28	薬物送達および鑑視適用のためのヒト皮膚の微細穿孔
US6142939A (en)	2000-11-07	Microporation of human skin for drug delivery and monitoring applications
JP3619453B2 (ja)	2005-02-09	微小穿孔された組織を通して電気穿孔するための装置
US20020169394A1 (en)	2002-11-14	Integrated tissue poration, fluid harvesting and analysis device, and method therefor
EP1563788B1 (de)	2015-02-18	Mikroperforation von menschlicher Haut zur Medikamentenverabreichung und Überwachungsanwendungen